Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF708 (ImmuneEditome ID:7562)

1. Gene summary of enriched editing regions for ZNF708

Gene summary

Gene information	Gene symbol	ZNF708
	Gene ID	7562
	GeneSynonyms	KOX8\|ZNF15\|ZNF15L1
	GeneCytomap	19p12
	GeneType	protein-coding
	GeneDescription	zinc finger protein 708\|ZNF15, ZNF15L1\|zinc finger protein 15-like 1 (KOX 8)
	GeneModificationdate	20230329
	UniprotID	P17019;M0R2V2;M0QYN4;M0R1G3
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:21274047-21275839:-	ENST00000611392.3	ENSG00000182141.8	ZNF708	intronic	AluSx,L1PB2,AluJo,AluSx4,AluYm1,MER57A-int	chr19:21274047-21275839:-.alignment
chr19:21279488-21280735:-	ENST00000611392.3	ENSG00000182141.8	ZNF708	intronic	L1PB,(GTTT)n,AluSz,AluSg,AluY	chr19:21279488-21280735:-.alignment
chr19:21285205-21288507:-	ENST00000611392.3	ENSG00000182141.8	ZNF708	intronic	AluSz,L1MA8,AluSq2,L1PA17,(TTCT)n	chr19:21285205-21288507:-.alignment
chr19:21304660-21306941:-	ENST00000602023.1	ENSG00000182141.8	ZNF708	splicing	AluJb,L1M4c,AluSc,AluSg	chr19:21304660-21306941:-.alignment
chr19:21316213-21316407:-	ENST00000356929.3	ENSG00000182141.8	ZNF708	intronic	AluSp	chr19:21316213-21316407:-.alignment
chr19:21316213-21316407:-	ENST00000598046.4	ENSG00000182141.8	ZNF708	intronic	AluSp	chr19:21316213-21316407:-.alignment
chr19:21316213-21316407:-	ENST00000601295.1	ENSG00000182141.8	ZNF708	intronic	AluSp	chr19:21316213-21316407:-.alignment
chr19:21316213-21316407:-	ENST00000602023.1	ENSG00000182141.8	ZNF708	intronic	AluSp	chr19:21316213-21316407:-.alignment
chr19:21316213-21316407:-	ENST00000611392.3	ENSG00000182141.8	ZNF708	intronic	AluSp	chr19:21316213-21316407:-.alignment
chr19:21322338-21322570:-	ENST00000356929.3	ENSG00000182141.8	ZNF708	intronic	AluSx	chr19:21322338-21322570:-.alignment
chr19:21322338-21322570:-	ENST00000598046.4	ENSG00000182141.8	ZNF708	intronic	AluSx	chr19:21322338-21322570:-.alignment
chr19:21322338-21322570:-	ENST00000601295.1	ENSG00000182141.8	ZNF708	intronic	AluSx	chr19:21322338-21322570:-.alignment
chr19:21322338-21322570:-	ENST00000602023.1	ENSG00000182141.8	ZNF708	intronic	AluSx	chr19:21322338-21322570:-.alignment
chr19:21322338-21322570:-	ENST00000611392.3	ENSG00000182141.8	ZNF708	intronic	AluSx	chr19:21322338-21322570:-.alignment

Top

2. Tumor-specific enriched editing regions for ZNF708

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000182141.8,ZNF708	BRCA	EAG	1.1850e-03
ENSG00000182141.8,ZNF708	STAD	EAG	2.7021e-03
ENSG00000182141.8,ZNF708	THCA	EAG	1.7604e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr19:21304660-21306941:-	BRCA	Path	EER	4.3469e-03	1.7254e-03	0.5106
ENSG00000182141.8,ZNF708	BRCA	Path	EAG	3.9023e-02	1.3848e-02	0.0789

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for ZNF708

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for ZNF708

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000182141.8,ZNF708

GBM

EAG

ENSG00000077809.8

chr7

74711031:74711109:74714856:74714916:74716893:74716950

-0.3877

1.4223e-03

2.7204e-08

-0.4245

Monocytes

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000182141.8,ZNF708

GBM

EAG

ENSG00000174652.13

chr19

9418504:9418631:9418761:9418895

-0.2535

3.7423e-02

6.0614e-06

-0.4079

ACIN1;ADAR;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SLBP;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_follicular_helper

GSVA_HALLMARK_PEROXISOME

ENSG00000182141.8,ZNF708

GBM

EAG

ENSG00000187145.10

chr1

150293868:150293898:150294334:150294449

-0.4718

2.9354e-05

1.6917e-09

-0.4537

T_cells_CD4_memory_activated

GSVA_HALLMARK_COAGULATION

ENSG00000182141.8,ZNF708

GBM

EAG

ENSG00000125970.7

chr20

34073609:34073635:34073818:34073866:34075873:34075921

0.3891

1.6975e-03

9.9651e-08

0.4061

ACIN1;ADAR;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SLBP;SND1;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184

T_cells_CD8

GSVA_HALLMARK_ALLOGRAFT_REJECTION

ENSG00000182141.8,ZNF708

GBM

EAG

ENSG00000127603.19

chr1

39435625:39435761:39436481:39436490:39437776:39438008

0.3446

3.3074e-03

5.1187e-07

0.4135

ACIN1;ADAR;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SAFB2;SLBP;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_CD8

GSVA_HALLMARK_COAGULATION

ENSG00000182141.8,ZNF708

PCPG

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215935:77216023:77216049:77216127:77216309:77216426:77216802

-0.1385

2.7550e-02

1.0491e-08

-0.4914

Mast_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000182141.8,ZNF708

PCPG

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215935:77216023:77216088:77216127:77216309:77216426:77216802

-0.1385

2.7550e-02

1.0491e-08

-0.4914

Mast_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000182141.8,ZNF708

PCPG

EAG

MEX

ENSG00000129657.10

chr17

77215909:77215935:77216023:77216127:77216179:77216309:77216426:77216802

-0.1242

4.7724e-02

3.6901e-08

-0.4665

Mast_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000182141.8,ZNF708

PCPG

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215935:77216023:77216127:77216127:77216309:77216426:77216802

-0.1421

2.2608e-02

2.9879e-08

-0.4692

Mast_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

ENSG00000182141.8,ZNF708

PCPG

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215935:77216023:77216114:77216127:77216309:77216426:77216802

-0.1368

3.2240e-02

3.3139e-08

-0.4747

Mast_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

More results

Top

5. Enriched editing regions and immune infiltration for ZNF708

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr19:21285205-21288507:-	ACC	EER	T_cells_regulatory_(Tregs)	9.5477e-03	-0.5643
ENSG00000182141.8,ZNF708	ACC	EAG	Mast_cells_activated	3.2908e-03	0.3861
chr19:21285205-21288507:-	BLCA	EER	Plasma_cells	1.7245e-02	-0.3259
ENSG00000182141.8,ZNF708	BLCA	EAG	T_cells_regulatory_(Tregs)	6.6962e-03	-0.1632
chr19:21285205-21288507:-	BRCA	EER	T_cells_CD4_memory_activated	1.6433e-02	-0.1355
chr19:21304660-21306941:-	BRCA	EER	T_cells_follicular_helper	4.0682e-02	0.3477
ENSG00000182141.8,ZNF708	BRCA	EAG	T_cells_gamma_delta	1.0317e-02	-0.0822
ENSG00000182141.8,ZNF708	CESC	EAG	NK_cells_activated	2.9668e-02	0.1978
ENSG00000182141.8,ZNF708	CHOL	EAG	T_cells_CD8	4.5102e-02	0.3749
chr19:21285205-21288507:-	COAD	EER	Eosinophils	1.7935e-03	0.5462
ENSG00000182141.8,ZNF708	COAD	EAG	Dendritic_cells_activated	8.4943e-04	0.2788
ENSG00000182141.8,ZNF708	DLBC	EAG	Dendritic_cells_activated	9.2807e-04	0.4673
chr19:21285205-21288507:-	ESCA	EER	T_cells_gamma_delta	5.3561e-05	0.3944
ENSG00000182141.8,ZNF708	ESCA	EAG	T_cells_gamma_delta	4.1555e-02	0.1871
ENSG00000182141.8,ZNF708	GBM	EAG	T_cells_regulatory_(Tregs)	3.6532e-03	0.2285
ENSG00000182141.8,ZNF708	HNSC	EAG	B_cells_memory	1.4989e-03	0.3197
chr19:21285205-21288507:-	KICH	EER	Dendritic_cells_activated	2.2893e-03	0.4632
ENSG00000182141.8,ZNF708	KIRC	EAG	T_cells_gamma_delta	1.0002e-02	-0.1589
ENSG00000182141.8,ZNF708	KIRP	EAG	NK_cells_activated	9.8277e-03	-0.1953
chr19:21285205-21288507:-	LAML	EER	Dendritic_cells_resting	9.7705e-05	0.5277
chr19:21285205-21288507:-	LGG	EER	T_cells_gamma_delta	1.1451e-03	0.1597
ENSG00000182141.8,ZNF708	LGG	EAG	T_cells_regulatory_(Tregs)	9.8826e-04	0.1430
ENSG00000182141.8,ZNF708	LIHC	EAG	T_cells_CD8	2.2491e-03	0.3697
chr19:21285205-21288507:-	LUAD	EER	T_cells_CD4_memory_resting	3.3537e-02	0.2544
ENSG00000182141.8,ZNF708	LUAD	EAG	T_cells_CD8	1.0629e-02	0.1456
ENSG00000182141.8,ZNF708	LUSC	EAG	B_cells_memory	3.5639e-02	0.1465
chr19:21304660-21306941:-	OV	EER	NK_cells_activated	3.8148e-02	-0.3625
ENSG00000182141.8,ZNF708	OV	EAG	T_cells_CD8	8.9822e-06	0.2736
ENSG00000182141.8,ZNF708	PAAD	EAG	T_cells_follicular_helper	4.0466e-02	0.1939
chr19:21285205-21288507:-	PCPG	EER	Macrophages_M1	2.8950e-02	-0.3805
chr19:21285205-21288507:-	PRAD	EER	Neutrophils	3.5533e-02	0.1445
ENSG00000182141.8,ZNF708	PRAD	EAG	Macrophages_M0	7.5314e-03	-0.1202
ENSG00000182141.8,ZNF708	SARC	EAG	T_cells_CD4_memory_resting	2.1760e-02	0.1764
ENSG00000182141.8,ZNF708	SKCM	EAG	NK_cells_resting	3.6645e-02	-0.1312
ENSG00000182141.8,ZNF708	STAD	EAG	Dendritic_cells_resting	4.5088e-02	0.1201
ENSG00000182141.8,ZNF708	TGCT	EAG	Dendritic_cells_resting	1.1153e-02	-0.2095
chr19:21285205-21288507:-	THCA	EER	T_cells_CD4_memory_activated	3.0613e-02	0.1935
ENSG00000182141.8,ZNF708	THCA	EAG	T_cells_CD4_memory_activated	2.9861e-02	0.0995
ENSG00000182141.8,ZNF708	THYM	EAG	T_cells_gamma_delta	6.2930e-04	0.3128
chr19:21285205-21288507:-	UCEC	EER	Macrophages_M0	4.0471e-02	0.4124
ENSG00000182141.8,ZNF708	UCS	EAG	B_cells_naive	4.2112e-02	-0.2857

Top

6. Enriched editing regions and immune gene sets for ZNF708

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000182141.8,ZNF708	BLCA	EAG	1.6378e-04	0.2254	2.8655e-02	0.1320	1.7673e-04	0.2243	7.1911e-06	0.2669
ENSG00000182141.8,ZNF708	BRCA	EAG	3.4862e-03	0.0936	1.6000e-02	0.0772	4.9808e-04	0.1115	1.6516e-04	0.1205
ENSG00000182141.8,ZNF708	DLBC	EAG	1.0263e-02	0.3709	1.2647e-02	0.3611	1.0067e-03	0.4644	1.2729e-03	0.4561

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr19:21285205-21288507:-	ACC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	4.2882e-02	0.4568
ENSG00000182141.8,ZNF708	ACC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	9.1446e-03	0.3453
ENSG00000182141.8,ZNF708	BLCA	GSVA_HALLMARK_APOPTOSIS	EAG	4.7873e-06	0.2718
chr19:21285205-21288507:-	BLCA	GSVA_HALLMARK_HEME_METABOLISM	EER	3.0941e-03	0.3988
ENSG00000182141.8,ZNF708	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	9.1329e-09	0.1830
chr19:21285205-21288507:-	BRCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.1002e-03	0.1836
chr19:21304660-21306941:-	BRCA	GSVA_HALLMARK_E2F_TARGETS	EER	1.7402e-03	0.5102
ENSG00000182141.8,ZNF708	CESC	GSVA_HALLMARK_HYPOXIA	EAG	9.6468e-03	0.2344
ENSG00000182141.8,ZNF708	CHOL	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EAG	6.9228e-03	0.4904
ENSG00000182141.8,ZNF708	COAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.6203e-02	0.2029
chr19:21285205-21288507:-	COAD	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.5630e-02	-0.4374
ENSG00000182141.8,ZNF708	DLBC	GSVA_HALLMARK_HYPOXIA	EAG	1.2729e-03	0.4561
chr19:21322338-21322570:-	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.9944e-02	0.3292
chr19:21285205-21288507:-	ESCA	GSVA_HALLMARK_SPERMATOGENESIS	EER	5.7278e-03	0.2758
ENSG00000182141.8,ZNF708	ESCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	2.1883e-03	0.2782
ENSG00000182141.8,ZNF708	GBM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.1124e-03	0.2555
chr19:21285205-21288507:-	GBM	GSVA_HALLMARK_HEME_METABOLISM	EER	1.5530e-02	0.2282
ENSG00000182141.8,ZNF708	HNSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	9.7576e-03	-0.2625
chr19:21285205-21288507:-	KICH	GSVA_HALLMARK_ANGIOGENESIS	EER	2.2499e-02	-0.3556
ENSG00000182141.8,ZNF708	KIRC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	2.6944e-02	0.1367
chr19:21285205-21288507:-	KIRC	GSVA_HALLMARK_ADIPOGENESIS	EER	3.1683e-02	0.2319
chr19:21285205-21288507:-	LAML	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.9276e-02	0.2824
chr19:21285205-21288507:-	LGG	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.6200e-02	0.1095
ENSG00000182141.8,ZNF708	LGG	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	2.1373e-03	0.1333
ENSG00000182141.8,ZNF708	LIHC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.3407e-02	-0.2788
ENSG00000182141.8,ZNF708	LUAD	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.1541e-02	-0.1440
ENSG00000182141.8,ZNF708	LUSC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.7699e-02	-0.1534
ENSG00000182141.8,ZNF708	OV	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	5.4386e-06	0.2799
chr19:21304660-21306941:-	OV	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.4920e-02	0.4201
chr19:21285205-21288507:-	OV	GSVA_HALLMARK_PEROXISOME	EER	9.8759e-05	0.2959
ENSG00000182141.8,ZNF708	PAAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.1651e-02	-0.2376
chr19:21285205-21288507:-	PCPG	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.4401e-03	-0.5320
ENSG00000182141.8,ZNF708	PRAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	4.7745e-03	0.1269
chr19:21285205-21288507:-	PRAD	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	1.3306e-03	-0.2190
ENSG00000182141.8,ZNF708	SARC	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.0763e-03	0.2494
ENSG00000182141.8,ZNF708	SKCM	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	7.6694e-03	0.1669
chr19:21285205-21288507:-	STAD	GSVA_HALLMARK_E2F_TARGETS	EER	1.3326e-04	0.2565
ENSG00000182141.8,ZNF708	STAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.9336e-06	0.2805
ENSG00000182141.8,ZNF708	TGCT	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.9184e-03	-0.2547
ENSG00000182141.8,ZNF708	THCA	GSVA_HALLMARK_P53_PATHWAY	EAG	1.5007e-02	0.1113
chr19:21285205-21288507:-	THCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.7824e-02	0.2116
ENSG00000182141.8,ZNF708	THYM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.1558e-04	0.3371
ENSG00000182141.8,ZNF708	UCEC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	6.5807e-03	0.2160
chr19:21285205-21288507:-	UCEC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	1.4002e-02	-0.4850
ENSG00000182141.8,ZNF708	UCS	GSVA_HALLMARK_MYOGENESIS	EAG	3.1674e-02	-0.3013
ENSG00000182141.8,ZNF708	UVM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	3.1431e-03	0.6128

Top

7. Enriched editing regions and drugs for ZNF708

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr19:21285205-21288507:-	ACC	AZD7762	EER	1.8454e-02	0.5212
ENSG00000182141.8,ZNF708	BLCA	CMK	EAG	5.8665e-04	-0.2060
ENSG00000182141.8,ZNF708	BRCA	IPA.3	EAG	4.4127e-05	0.1307
chr19:21304660-21306941:-	BRCA	A.443654	EER	9.5146e-03	-0.4322
chr19:21285205-21288507:-	BRCA	Cyclopamine	EER	3.2240e-03	0.1665
ENSG00000182141.8,ZNF708	CESC	Erlotinib	EAG	2.2313e-02	-0.2076
ENSG00000182141.8,ZNF708	CHOL	JNJ.26854165	EAG	3.2251e-03	-0.5282
ENSG00000182141.8,ZNF708	COAD	LFM.A13	EAG	4.6449e-02	-0.1686
chr19:21285205-21288507:-	COAD	LFM.A13	EER	1.2546e-03	-0.5612
ENSG00000182141.8,ZNF708	DLBC	Bosutinib	EAG	6.4414e-04	0.4845
chr19:21322338-21322570:-	ESCA	Cisplatin	EER	4.0863e-02	0.3425
chr19:21285205-21288507:-	ESCA	BAY.61.3606	EER	1.7312e-02	-0.2388
ENSG00000182141.8,ZNF708	ESCA	Docetaxel	EAG	6.8526e-03	-0.2466
ENSG00000182141.8,ZNF708	GBM	CGP.082996	EAG	4.3208e-08	-0.4164
chr19:21285205-21288507:-	GBM	BAY.61.3606	EER	7.7756e-03	-0.2503
ENSG00000182141.8,ZNF708	HNSC	JW.7.52.1	EAG	9.4142e-03	-0.2638
ENSG00000182141.8,ZNF708	KICH	Dasatinib	EAG	6.2367e-04	-0.4432
chr19:21285205-21288507:-	KICH	JW.7.52.1	EER	1.7313e-03	-0.4743
chr19:21285205-21288507:-	KIRC	GW.441756	EER	1.4850e-03	-0.3375
ENSG00000182141.8,ZNF708	KIRC	Cyclopamine	EAG	3.7787e-02	0.1287
ENSG00000182141.8,ZNF708	KIRP	BI.D1870	EAG	2.8785e-02	-0.1658
chr19:21285205-21288507:-	LAML	EHT.1864	EER	5.0507e-04	0.4785
ENSG00000182141.8,ZNF708	LAML	GDC0941	EAG	2.4057e-02	0.2059
chr19:21285205-21288507:-	LGG	BMS.509744	EER	6.4385e-03	0.1340
ENSG00000182141.8,ZNF708	LGG	BI.2536	EAG	1.2801e-19	0.3804
ENSG00000182141.8,ZNF708	LIHC	Dasatinib	EAG	1.1817e-03	-0.4121
ENSG00000182141.8,ZNF708	LUAD	BAY.61.3606	EAG	1.0525e-02	0.1458
chr19:21285205-21288507:-	LUAD	BI.2536	EER	3.2977e-06	0.5236
ENSG00000182141.8,ZNF708	LUSC	JNJ.26854165	EAG	6.7183e-03	-0.1883
ENSG00000182141.8,ZNF708	MESO	GSK269962A	EAG	2.5983e-03	-0.3983
chr19:21304660-21306941:-	OV	Bosutinib	EER	3.3630e-02	-0.3708
chr19:21285205-21288507:-	OV	CMK	EER	8.6088e-04	-0.2548
ENSG00000182141.8,ZNF708	OV	AZ628	EAG	6.2915e-05	-0.2474
ENSG00000182141.8,ZNF708	PAAD	FTI.277	EAG	1.1813e-02	-0.2372
chr19:21285205-21288507:-	PCPG	BIRB.0796	EER	1.4384e-02	-0.4222
chr19:21285205-21288507:-	PRAD	AG.014699	EER	1.7836e-03	-0.2134
ENSG00000182141.8,ZNF708	PRAD	Imatinib	EAG	5.7266e-04	-0.1546
ENSG00000182141.8,ZNF708	SARC	Lapatinib	EAG	1.1889e-03	-0.2473
chr19:21285205-21288507:-	STAD	JNJ.26854165	EER	9.0737e-04	0.2237
ENSG00000182141.8,ZNF708	STAD	BMS.509744	EAG	1.8437e-07	-0.3060
ENSG00000182141.8,ZNF708	TGCT	Erlotinib	EAG	9.2086e-04	0.2714
ENSG00000182141.8,ZNF708	THCA	Embelin	EAG	8.1376e-04	0.1528
chr19:21285205-21288507:-	THCA	BIBW2992	EER	1.4107e-02	-0.2191
ENSG00000182141.8,ZNF708	THYM	Axitinib	EAG	1.6680e-04	0.3426
ENSG00000182141.8,ZNF708	UCEC	CGP.082996	EAG	5.2793e-03	-0.2216
chr19:21285205-21288507:-	UCEC	Midostaurin	EER	9.8167e-03	0.5063
ENSG00000182141.8,ZNF708	UCS	AS601245	EAG	2.1955e-03	-0.4193
ENSG00000182141.8,ZNF708	UVM	Embelin	EAG	1.8622e-03	0.6379

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType